Rosiglitazone: safety and efficacy in combination with insulin in poorly controlled type 2 diabetes mellitus patients treated with insulin alone

Journal of Diabetes and its Complications

Volumn 21, Issue 1, 2007, Pages 1-6

  Garg, Ranjna ^a   Gopal, Jayanthi ^a   Jones, Geraint Rhys ^a  

^a ROYAL BLACKBURN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; ROSIGLITAZONE; TRIACYLGLYCEROL;

ADD ON THERAPY; ADULT; AGED; ANKLE EDEMA; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; WEIGHT GAIN;

AGED; BLOOD GLUCOSE; BLOOD PRESSURE; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIPIDS; MIDDLE AGED; PATIENT SELECTION; SAFETY; THIAZOLIDINEDIONES; WEIGHT GAIN;

EID: 33845668017     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2005.10.004     Document Type: Article

References (37)

1. Actos (pioglitazone hydrochloride). [package insert] (2000), Takeda Pharmaceuticals America, Lincolnshire, IL
2. Avandia (rosiglitazone maleate). [package insert] (2000), GlaxoSmithKline Pharmaceuticals, Philadelphia, PA
3. Campbell I.W. Antidiabetic drugs present and future: Will improving insulin resistance benefit cardiovascular risk in type-2 diabetes mellitus?. Drugs 60 5 (2000 Nov) 1017-1028
4. Cavaghan M.K., Ehrmann D.A., Byrne M.M., and Polonsky K.S. Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. Journal of Clinical Investigation 100 (1997) 530-537
5. Chitturi S., Abeygunasekera S., Farrell G.C., Holmes-Walker J., Hui J.M., Fung C., Karim R., Lin R., Samarasinghe D., Liddle C., Weltman M., and George J. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 35 2 (2002 Feb) 373-379
6. Delea T.E., Edelsberg J.S., Hagiwara M., Oster G., and Phillips L.S. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: A retrospective cohort study. Diabetes Care 26 (2003) 2983-2989
7. Falchuk K.R., Fiske S.C., Haggitt R.C., Federman R., and Trey C. Pericentral hepatic fibrosis and intracellular hyalin in diabetes mellitus. Gastroenterology 78 (1980) 535-541
8. Finegood D.T., McArthur M.D., Kojwang D., Thomas M.J., Topp B.G., Leonar T., and Buckingham R.E. β-Cell mass dynamics in Zucker diabetic fatty rats: Rosiglitazone prevents the rise in net cell death. Diabetes 50 (2001) 1021-1029
9. Fronseca V., Rosenstock J., Patwardhan R., and Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type two diabetes mellitus. Journal of the American Medical Association 283 (2000) 1695-1702
10. Gitlin N., Julie N.L., Spurr C.L., Lim K.N., and Juarbe H.M. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Annals of Internal Medicine 129 (1998) 36-38
11. Henry R.R. Thiazolidinediones. Endocrinol Metab Clin North Am 26 (1997) 553-573
12. Honisett S.Y., Stojanovska L., Sudhir K., Kingwell B.A., Dawood T., and Komeosaroff P.A. Rosiglitazone lowers blood pressure and increases arterial compliance in postmenopausal women with type 2 diabetes. Diabetes Care 26 11 (2003 Nov) 3194-3195
13. Kahn S.E. Clinical review: The importance of β-cell failure in the development and progression of type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 86 (2001) 4047-4058
14. Kawai K., Kawasaki-Tokui Y., Odaka T., Tsuruta F., Kazui M., Iwabuchi H., Nakamura T., Kinoshita T., Ikeda T., Yoshioka T., Komai T., and Nakamura K. Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs. Arzneimittelforshung 47 (1997) 356-368
15. Kelly I.E., Han T.S., Walsh K., et al. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 22 (1999) 288-293
16. Lebovitz H.E., Kreider M., and Freed M.I. Evaluation of liver function in type 2 diabetic patients during clinical trials. Diab Care 25 (2002) 815-821
17. Mäkimattila S., Nikkilä K., and Yki-Järvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with non-insulin-dependent diabetes mellitus. Diabetologia 42 (1999) 406-412
18. Martens F.M., Visseren F.L., Lemay J., et al. Metabolic and additional vascular effects of thiazolidinediones. Drugs 62 (2002) 1463-1480
19. Matthews D.R., Cull C.A., Stratton I.M., Holman R.R., and Turner R.C. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabetic Medicine 15 (1998) 297-303
20. Miyazaki Y., Glass L., Triplitt C., Matsuda M., Cusi K., Mahankali A., Mahankali S., Mandarino L.J., and DeFronzo R.A. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients. Diabetologia 44 (2001) 2210-2219
21. Muscelli E., Natali A., Bianchi S., Bigazzi R., Galvan A.Q., Sironi A.M., Frascerra S., Ciociaro D., and Ferrannini E. Effect of insulin on renal sodium and uric acid handling in essential hypertension. American Journal of Hypertension 9 (1996) 746-752
22. Nakamura T., Funahashi T., Yamashita S., et al. Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation: Double-blind placebo-controlled trial. Diabetes Research and Clinical Practice 54 (2001) 181-190
23. Neuschwander-Tetri B.A. Fatty liver and nonalcoholic steatohepatitis. Clinical Cornerstone 3 6 (2001) 47-57
24. Neuschwander-Tetri B.A., Brunt E.M., Wehmeier K.R., Oliver D., and Bacon B.R. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38 4 (2003 Oct) 1008-1017
25. Ono M., Ikegami H., Fujisawa T., Nojima K., Kawabata Y., Nishino M., Taniguchi H., Itoi-Babaya M., Babaya N., Inoue K., and Ogihara T. Improvement of liver function parameters in patients with type 2 diabetes treated with thiazolidinediones. Metabolism 54 4 (2005 Apr) 529-532
26. Phillips L.S., Grunberger G., Miller E., Patwardhan R., Rappaport E.B., Salzman A., and Rosiglitazone Clinical Trials Study Group. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 24 2 (2001 Feb) 308-315
27. Raji A., Seely E.W., Bekins S.A., Williams G.H., and Simonson D.C. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 26 1 (2003 Jan) 172-178
28. Raskin P., Rendell M., Riddle M.C., Dole J.F., Freed M.I., and Rosenstock J. A randomised trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 24 (2001) 1226-1232
29. Roy R., Navar M., Palomeno G., and Davidson M.B. Real world effectiveness of rosiglitazone added to maximal (tolerated) doses of metformin and a sulfonylurea agent: A systematic evaluation of triple oral therapy in a minority population. (Brief report). Diabetes Care 27 (2004) 1741-1742
30. Spiegelman B.M. PPAR-γ: Adipogenic regulator and thiazolidinedione receptor. Diabetes 47 (1998) 507-514
31. Stenvinkel P., Bolinder J., and Alvestrand A. Effects of insulin on renal haemodynamics and the proximal and distal tubular sodium handling in healthy subjects. Diabetologia 35 11 (1992 Nov) 1042-1048
32. Stratton I.M., Adler A.I., Neil H.A.W., Matthews D.R., Manley S.E., Cull C.A., Hadden D., Turner R.C., and Holman R.R. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. British Medical Journal 321 (2000) 405-412
33. Strowig S.M., Aviles-Santa M.L., and Raskin P. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes. Diabetes Care 25 10 (2002, Oct) 1691-1698
34. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type-2 diabetes (UKPDS 33). Lancet 352 (1998) 83753
35. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type-2 diabetes (UKPDS 38). British Medical Journal 317 (1998) 705-713
36. Valensi P. Rosiglitazone: A clinical development focused on cardio-vascular prevention. Annales d'Endocrinologie (Paris) 63 2 Pt. 2 (2002 Apr) 1S35-1S40
37. Watkins P.B., and Whitecomb R.W. Hepatic dysfunction associated with troglitazone. New England Journal of Medicine 338 (1998) 916-917